Showing 2541-2550 of 10548 results for "".
Considerations for the Use of Biologics in Children with Atopic Dermatitis
https://practicaldermatology.com/videos/dermatology-hub-neuroimmune-network/derm-hub/37152/Dawn Zhang Eichenfield, MD, PhD, a dermatologist at Rady Children's Hospital-San Diego and an assistant clinical professor of dermatology at the University of California, San Diego, School of Medicine, explains the most important factors to understand when prescribing biologics for pediatric atopicA Case Presentation of Prurigo Nodularis
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/derm-hub/37154/Alina Bridges, DO, Director of Dermatopathology & Associate Professor in the Department of Dermatology and Anatomic Pathology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, presents a case study involving a patient who had been on multiple treatments to present prurituBiologics Preferred after MACE in PsO, Plus More
https://practicaldermatology.com/series/dermwire-tv/biologics-preferred-after-mace-in-pso-plus-more/37882/In this edition of DermwireTV, new research shows biologic use use after MACE is persistent, signaling strong patient preference; a new study shows that early stress may raise lifelong psoriasis risk; and a new C-Suite Chat highlights a new antibody showing promise in treating atopic dermatitisDWTV Extra: Phase 3 Data on Roflumilast for AD, PsO
https://practicaldermatology.com/videos/dermwire-tv/dwtv-extra-phase-3-data-on-roflumilast-for-ad-pso/35925/Study investigator Melinda Gooderham, MD, talks about the Phase 3 trials of roflumilast cream 0.15% for adults and children down to age 6 with atopic dermatitis and roflumilast foam 0.3% for patients older than 12 with psoriasis of the scalp and body.The Impact of Clascoterone Topical Cream, 1%
https://practicaldermatology.com/issues/april-2025/the-impact-of-clascoterone-topical-cream-1/35605/Clascoterone topical cream, 1% (Winlevi, Sun Pharmaceuticals, Inc.) approved by the US Food and Drug Administration (FDA) in 2020 as the first novel drug introduced for the treatment of acne vulgaris since 1982, is indicated in the US for patients 12 years of age and older.Dupilumab's Impact on Height, 40-GEP for HNcSCC Lead Posters at Maui Derm
https://practicaldermatology.com/programs/practical-dermatology/dupilumabs-impact-on-height-40-gep-for-hncscc-lead-posters-at-maui-derm/32916/The impact of dupilumab on children’s height and the 40-gene expression profile (40-GEP) test for patients with cutaneous squamous cell carcinoma of the head and neck (HNcSCC) were the topics of the top two posters in the “Late Breakers 2025” session at Maui Derm 2025 in Maui, Hawaii.Acne and Rosacea: Dr. Baldwin
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/acne-and-rosacea-dr-baldwin/32693/Hilary Baldwin, MD, talks about a topic that she did not have time to cover during "Update 2025: Acne and Rosacea" at Maui Derm 2025—emergency contraception in patients on isotretinoin.DermwireTV 2024 Year in Review
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-2024-year-in-review/32206/We look back at the top stories of 2024 in the Dermatology and Aesthetics markets. Several new products were approved or launched in atopic dermatitis, rosacea, prurigo nodularis, and hidradenitis suppurativa; new clinical guidelines were made for AD, acne care, and skin cancer; and a new study raisDermWireTV: Diagnosing Melanoma Using Deep-Learning Model; New Adbry Approval
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-diagnosing-melanoma-using-deep-learning-model-new-adbry-approval/26445/In this week's DermWireTV, researchers develop a novel deep-learning model designed to more accurately diagnose melanoma; LEO Pharma receives a new approval for atopic dermatitis drug Adbry; and in our PA Perspectives segment, Andrew Mastro discusses how to build an inflammatory clinic.American Academy of Dermatology 2024
Meeting Wrap-Uphttps://practicaldermatology.com/cme/dermatology/meeting-coverage-aad-2024/24461/Practical Dermatology® was at the American Academy of Dermatology 2024 Annual Meeting in San Diego (AAD 2024) reporting on the latest research findings on innovative therapies and insights into managing complex dermatological disorders. From pioneering trials showcasing the efficacy of novel topical